Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $44.00.

Several research analysts have commented on ASMB shares. Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Guggenheim restated a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, May 4th. Finally, Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research report on Monday, June 15th.

Assembly Biosciences Stock Up 1.3%

NASDAQ:ASMB opened at $25.55 on Tuesday. The stock has a fifty day simple moving average of $25.98 and a 200 day simple moving average of $27.71. The firm has a market capitalization of $405.99 million, a price-to-earnings ratio of -232.25 and a beta of 1.08. Assembly Biosciences has a 1-year low of $16.90 and a 1-year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The firm had revenue of $8.21 million for the quarter, compared to the consensus estimate of $9.27 million. Equities analysts predict that Assembly Biosciences will post 1.9 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Informed Momentum Co LLC grew its holdings in shares of Assembly Biosciences by 1.6% during the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after acquiring an additional 451 shares in the last quarter. ADAR1 Capital Management LLC boosted its position in Assembly Biosciences by 4.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 800 shares during the last quarter. Geode Capital Management LLC grew its stake in Assembly Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after purchasing an additional 1,212 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Assembly Biosciences by 4.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Palumbo Wealth Management LLC increased its position in Assembly Biosciences by 7.2% in the 4th quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock worth $1,269,000 after purchasing an additional 2,507 shares during the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.